Related Experiment Videos
Technology evaluation: Belatacept, Bristol-Myers Squibb.
Bernard Vanhove1, Jean-Paul Soulillou
1INSERM U643, Institut de Transplantation et de Recherche en Transplantation, 30 Bld J Monnet, 44093 Nantes, France. Bernard.Vanhove@univ-nantes.fr
Current Opinion in Molecular Therapeutics
|August 27, 2005
Summary
Belatacept, a novel fusion protein, inhibits T-cell co-stimulation to prevent solid organ transplant rejection. Ongoing phase III trials are evaluating its efficacy in transplant recipients.
Area of Science:
- Immunology
- Transplantation Medicine
- Drug Development
Background:
- Solid organ transplant rejection remains a significant clinical challenge.
- Current immunosuppressive therapies carry risks of infection and malignancy.
- Targeting lymphocyte co-stimulation offers a novel approach to prevent rejection.
Purpose of the Study:
- To evaluate belatacept, a CTLA4-Ig fusion protein, for preventing solid organ transplant rejection.
- To investigate the mechanism of belatacept in inhibiting T-cell activation.
Main Methods:
- Belatacept is a soluble fusion protein engineered from CTLA4 and an immunoglobulin (Ig) tail.
- It incorporates specific amino acid changes (A29Y and L104E) for enhanced binding.
- The drug functions by inhibiting CD28-mediated lymphocyte co-stimulation.
Main Results:
- Belatacept demonstrated the potential to inhibit T-cell co-stimulation.
- Pre-clinical and early clinical data suggest efficacy in preventing transplant rejection.
Conclusions:
- Belatacept represents a promising therapeutic candidate for solid organ transplant recipients.
- Phase III clinical trials are underway to confirm its safety and efficacy.